929872-80-0

Upstream product

• 70642-86-3 N-(tert-butoxycarbonyl)-D-tyrosine 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 

Downstream Products

• 1012341-50-2 (2R,4S)-5-[(1,1‘-biphenyl)-4-yl]-4-((tert-butoxycarbonyl)amino)-2-methylpentanoic acid 
• 149709-61-5 (2S,4S)-5-biphenyl-4-yl-4-tert-butoxycarbonylamino-2-methylpentanoic acid ethyl ester 
• 149709-58-0 (R)-α-<<(1,1-dimethylethoxy)carbonyl>amino><1,1'-biphenyl>-4-propanal 
• 1383027-39-1 C₁₇H₂₃F₃N₂O₇S 
• 929872-79-7 C₂₃H₃₅N₃O₆Si 
• 929872-82-2 2-(trimethylsilyl)ethyl (4R)-4-[tert-butoxycarbonyl(methyl)amino]-5-(4-methoxyphenyl)-3-oxopentanoate 

Relevant academic research and scientific papers

An effective route to (-)-aphanorphine using D-tyrosine as a chiral building block

A stereoselective approach toward a naturally occurring alkaloid, (-)-aphanorphine, has been achieved via a series of reactions from Boc-D-tyrosine. Georg Thieme Verlag Stuttgart.

Preparation method of anti-heart-failure drug intermediate

The invention discloses a preparation method of an anti-heart-failure drug intermediate (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-((tertbutyloxycarbonyl)amino)-2-methylpentanoic acid. Under catalysis of a transition metal catalyst bis(dicyclopentadiene)rhodium tetrafluoroborate and a ligand (CK004), butoxy carbonyl-D-tyrosine which is used as a raw material undergoes diastereoselective hydrogenation synthesis by the use of hydrogen to obtain chiral center; and a product obtained after recrystallization of the chiral center and hydroxide radical form a leaving group by the use of trifluoromethanesulfonic anhydride; and an intermediate V undergoes a coupling reaction by the use of phenylboronic acid so as to obtain the finished product. The invention provides a brand-new synthesis route of the anti-heart-failure drug intermediate. The reaction steps are easy to control, and stable industrial production preparation can be realized.

NEPRILYSIN INHIBITORS

In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.